DUBLIN – As its name suggests, Glycoera AG aims to kickstart a new era in protein glycoengineering, and it has closed a CHF45 million (US$49 million) series A round to further its ambition of developing biologic drugs with defined glycosylation profiles that are an intrinsic aspect of their mechanisms.